Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating three fixed doses of extended-release paliperidone for bipolar I disorder. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Mood Disorders

Drugs mentioned

• Paliperidone Extended Release (paliperidone extended-release)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Bipolar Disorder, Mood Disorders | Phase 3 | Status: COMPLETED